Skip to main content
BFRI
NASDAQ Life Sciences

Biofrontera Q3: Revenue Up 30% to $9.1M, But Going Concern and New Nasdaq Equity Deficiency

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.7
Mkt Cap
$10.398M
52W Low
$0.555
52W High
$1.66
52W Position info
26% above low
Off High info
58% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

BFRI sits 26% above its 52-week low of $0.555 on elevated volume (1.9× avg).

Summary

Biofrontera's Q3 revenue rose 29.8% to $9.1 million and gross margin improved to 74.4%, but cash fell to $3.2 million, management flagged substantial going-concern doubt, and a $0.2 million stockholders' deficit puts it out of compliance with Nasdaq's minimum equity rule.


Key Events · Earnings and Guidance · BFRI

  • Q3 Revenue Up 29.8% to $9.1M

    Net product revenue was $9.1 million versus $7.0 million a year ago, but about $1.6 million came from orders pulled into early July 2026 ahead of ITC supply restrictions; excluding those, unit volume was comparable to the prior year.

  • Going Concern and Thin Cash

    Cash and equivalents fell to $3.2 million at September 30, 2026 from $6.4 million at December 31, 2025. Management states existing cash plus expected operating cash is not sufficient to fund operations for one year and that its plans do not alleviate substantial doubt.

  • New Nasdaq Equity Deficiency

    A $0.2 million stockholders' deficit leaves the company below Nasdaq Rule 5550(b)(1)'s $2.5 million minimum equity and outside both alternatives ($35 million market value or $0.5 million net income). It expects a notification letter and intends to submit a compliance plan.

  • Margins Improve on New Cost Structure

    Gross margin rose to 74.4% in Q3 2026 from 70.7%, and to 78.0% for nine months from 67.7%, as the Strategic Transaction replaced the 25%-of-net-revenue transfer price with Ameluz direct cost plus a 12% earnout.


Analysis · BFRI · Life Sciences

Revenue growth is real but partly borrowed from the future: about $1.6 million of Q3's $9.1 million came from customers stocking up in early July before ITC supply restrictions bit, and excluding that, unit volume was flat year over year. The bigger issue is the balance sheet. Cash fell to $3.2 million from $6.4 million at year-end, and management states plainly that existing cash plus expected operating cash will not fund the next twelve months — substantial doubt about going concern, with the $4.8 million of convertible notes due November 22, 2027 adding to the pressure. A $0.2 million stockholders' deficit also puts the company out of compliance with Nasdaq's $2.5 million minimum equity rule, and it expects a deficiency letter after this filing. The one genuine bright spot is margin: the Strategic Transaction cut Ameluz unit costs enough to lift gross margin to 74.4% from 70.7%, and the sBCC approval gives a new label to launch into later in Q4 2026 through Q1 2027 — but that launch needs cash the company does not currently have.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BFRI was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $0.55 to $1.66. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BFRI - Latest Insights

BFRI
Nov 13, 2026, 8:03 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.813
Real-time Price: $0.700 info
Change: -$0.113 (-14%) info
Market Cap: $10.398M info
BFRI
Oct 08, 2026, 9:25 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.9722
Real-time Price: $0.700 info
Change: -$0.2722 (-28%) info
Market Cap: $10.398M info
BFRI
Sep 14, 2026, 9:29 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.55
Real-time Price: $0.700 info
Change: -$0.850 (-55%) info
Market Cap: $10.398M info
BFRI
Aug 13, 2026, 4:41 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.27
Real-time Price: $0.700 info
Change: -$0.570 (-45%) info
Market Cap: $10.398M info
BFRI
Aug 13, 2026, 8:51 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.24
Real-time Price: $0.700 info
Change: -$0.540 (-44%) info
Market Cap: $10.398M info